多发性硬化症的疾病修饰疗法:对rituximab的重点审查
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Basic & clinical pharmacology & toxicology
|August 11, 2023
概括
利图西马布是一种有效的非标签治疗复发性复发性多发性硬化症 (RRMS),减少复发和MRI病变. 尽管它是有效的,但监管部门的批准仍然是广泛使用的障碍.
科学领域:
- 神经免疫学 神经免疫学
- 临床神经学 临床神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 治疗已经显著发展,与Rituximab作为一个流行的非标签B细胞疗法出现.
- 越来越多的证据支持rituximab在治疗多发性硬化症方面的有效性.
研究的目的:
- 审查和总结关于利图西马布治疗复发性复发性多发性硬化症 (RRMS) 的现有证据.
主要方法:
- 使用PubMed对成年RRMS研究进行了系统的文献搜索.
- 通过ClinicalTrials.gov.gov确定正在进行的临床试验.
- 从评论文章中收集了其他数据.
主要成果:
- 与已批准的多发性硬化疗法相比,rituximab显示了较少的临床复发和减少的MRI对比增强病变.
- 观察性研究和临床试验,包括一项由研究人员发起的大型RCT,支持Rituximab的疗效.
- 尽管有积极的发现,但制造商终止了行业赞助的试验.
结论:
- 利图西马布是一种可行的一线或二线治疗选择,用于活跃的,不进展的MS.
- 在许多地区,Rituximab在MS治疗中的广泛采用受到其非标签地位和监管批准挑战的限制.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Rheumatic Heart Disease III: Medical Management
13
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
13
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K


